Uveitis Treatment: Steroid Drops, Injections and Recovery

How Is Uveitis Treated?

Most uveitis is treated with steroids, which calm the inflammation. Steroid eye drops are the most common treatment, but drops are usually not enough when the inflammation is further back in the eye. That needs steroid injections in or around the eye, a small implant that releases steroid slowly, or steroid tablets. When uveitis affects both eyes, keeps coming back, responds poorly to steroids or threatens sight, doctors add medicines that calm the immune system so that less steroid is needed. When an infection is the cause, it is treated with antibiotics, antivirals or other anti-infection medicines, with or without steroids.

How Long Does Uveitis Take to Heal?

It depends on the type. Most attacks of anterior uveitis settle within six to eight weeks. Symptoms often ease within a few days of starting treatment, but the drops need to continue for longer while the inflammation clears. Uveitis at the back of the eye tends to heal more slowly, and some people need treatment for months or years. If the inflammation comes back within three months of stopping treatment, doctors call it chronic uveitis.

Can Uveitis Be Cured?

An attack can settle completely, and many people never have another one. About 1 in 3 people with anterior uveitis have repeat attacks. No treatment can promise that uveitis will not come back, but when an infection or another treatable condition is the cause, treating it can clear the uveitis. Chronic uveitis is usually kept under control rather than cured, and some people need medicine for a long time to keep it quiet.

When Is Uveitis an Emergency?

See an eye doctor the same day if you have a red, painful eye, sensitivity to light, blurred vision, or new floaters or flashes of light. Go to an emergency room now if you suddenly cannot see, if severe eye pain comes with a headache or feeling sick, if a chemical has splashed into your eye, or if you have injured the eye. If you have had uveitis before and the symptoms come back, do not restart old drops on your own, even if you have a spare bottle at home, unless your eye doctor has given you a written plan for this. Get checked first.

What to Avoid With Uveitis

• Stopping steroid drops suddenly or changing the dose yourself. Your eye doctor will lower it gradually.
• Driving while your vision is blurred, including after dilating drops.
• Wearing contact lenses while your eye is red and sore.
• Smoking. In a study of more than 1,100 eye patients, smokers had about twice the odds of uveitis, and the National Eye Institute lists smoking as a risk factor.
• Skipping follow-up visits. Steroids can raise eye pressure and cause cataract, and regular checks pick these up.

Tinted glasses or sunglasses can ease light sensitivity during an attack.

Netra Restoration Therapy is supportive care offered alongside the treatment your uveitis specialist prescribes. It does not replace steroid or immune treatment, and a new attack needs your eye doctor first. Tell your specialist about any herbs or supplements you take, because some can interact with medicines.

Why Treatment for Uveitis Should Be Multi-Factorial

A single-factor model is rarely sufficient for uveitis. Some patients have inflammation primarily in the front of the eye, while others have retinal, choroidal, vitreous, or optic-nerve involvement. Some have a known systemic inflammatory condition, while others have no clear trigger. Some experience one episode that resolves, while others experience a recurring pattern that becomes part of their visual life. Because the eye is a highly vascular, immune-sensitive, and neurologically active organ, inflammation can arise from multiple converging pathways.

A multi-factorial approach recognizes that uveitis is not only about visible inflammatory cells in the eye. It is also about the conditions that allow immune cells to enter, the signals that recruit and activate them, the vascular changes that increase leakage, the oxidative environment that determines tissue vulnerability, the repair capacity of ocular cells, and the systemic terrain that may keep the inflammatory threshold low. For this reason, an integrative uveitis strategy should not be narrowly framed around one tissue or one symptom. It should consider the full inflammatory ecosystem.

Immune Dysregulation and Loss of Ocular Immune Quiet

The healthy eye uses multiple mechanisms to maintain immune quiet. Ocular immune privilege, local immune-regulatory mediators, the blood-aqueous barrier, the blood-retinal barrier, and the specialized behavior of retinal and uveal cells all help prevent unnecessary inflammatory damage. In uveitis, these mechanisms can become overwhelmed or misdirected. T helper cell activation, macrophage recruitment, cytokine amplification, and antigen-specific immune responses may participate depending on the type of uveitis.

From an NRT perspective, immune support is not simply suppression. A regulated immune system can respond appropriately without creating unnecessary collateral damage. This distinction matters because recurrent uveitis often reflects an immune system that has difficulty returning to baseline after activation. Controlling that is the job of your specialist's treatment; NRT offers supportive care for sleep, stress and nutrition and has not been shown to reduce inflammation in the eye.

Blood-Aqueous and Blood-Retinal Barrier Disruption

The blood-aqueous barrier helps regulate what enters the anterior chamber, while the blood-retinal barrier protects the neural retina from excess plasma proteins, inflammatory cells, and circulating mediators. When these barriers are disturbed, fluid, proteins, immune cells, and cytokines may enter ocular compartments where they do not belong. This can contribute to haze, cells and flare, retinal leakage, macular swelling, and prolonged visual instability.

A barrier-focused model is especially important in intermediate, posterior, and pan-uveitic patterns, where retinal leakage and macular involvement may affect vision. Even when the acute inflammatory phase quiets, a compromised barrier can leave the eye more vulnerable to future reactivation. Controlling the inflammation with your specialist's treatment is the main way to protect these barriers; integrative care has not been shown to strengthen them.

Retinal and Choroidal Microcirculation

The uvea is one of the most vascular tissues in the body. The choroid supplies the outer retina and supports photoreceptor metabolism, while the retinal circulation nourishes the inner retina. Inflammatory activation can alter vascular tone, endothelial function, capillary permeability, and local oxygen delivery. These changes can be particularly relevant when uveitis is accompanied by retinal vasculitis, choroiditis, macular edema, optic-disc leakage, or ischemic stress.

In uveitis, blood vessels are not only damaged by inflammation; they also take part in leakage, the movement of immune cells into the eye, and tissue recovery. NRT has not been shown to change blood flow in the eye.

Oxidative Stress and Mitochondrial Vulnerability

Inflammation generates oxidative stress through activated immune cells, reactive oxygen species, mitochondrial strain, and tissue-level metabolic demand. The retina, uvea, and optic nerve are particularly vulnerable because they have high energy requirements and delicate cellular architecture. Photoreceptors, retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial cells all depend on mitochondrial stability and redox balance.

When oxidative stress exceeds the eye's capacity to neutralize it, inflammation may become more damaging and recovery may slow. This is one reason patients can feel that vision remains dim, unstable, hazy, or fatigued even after obvious redness or pain improves. NRT pays attention to general health factors such as diet, sleep and stress; it has not been shown to protect the eye from repeated inflammation.

Cytokine Amplification and Inflammatory Memory

Cytokines such as IL-6, TNF-alpha, IL-17, IL-23, interferon-gamma, chemokines, and related inflammatory mediators help coordinate immune activity in uveitis. When cytokine signaling becomes amplified, it may recruit more immune cells, increase vascular permeability, activate resident ocular cells, and sustain inflammation. Over time, recurrent inflammatory exposure may create a form of tissue memory in which the ocular environment becomes easier to reactivate.

Your specialist's treatment aims to control the whole inflammatory process, not only the visible episode. Alongside it, NRT pays attention to sleep, stress, digestion, nutrition and other general health factors that many patients link with their flares; it has not been shown to calm inflammation in the eye.

Autonomic Stress Physiology and Neuroimmune Signaling

Many patients notice that inflammatory flares occur during periods of stress, sleep disruption, illness, overwork, hormonal fluctuation, or systemic exhaustion. This does not mean stress is the only cause of uveitis. It means that the nervous system and immune system communicate continuously. Sympathetic overactivation, reduced parasympathetic recovery, poor sleep, and chronic stress physiology may influence immune threshold, vascular tone, pain sensitivity, and inflammatory resolution.

NRT offers stress-management, sleep and daily-rhythm guidance as part of general supportive care. It has not been shown to reduce flares, so it does not replace your specialist's treatment. The eye is not isolated from the nervous system, and many patients notice that stress and poor sleep come before a flare.

Systemic Inflammatory Terrain

Uveitis may occur in isolation, but it is also associated with systemic inflammatory and immune-mediated conditions. Digestive inflammation, joint inflammation, skin inflammation, vascular inflammation, infections, post-infectious immune patterns, and constitutional immune tendencies may all influence the ocular environment. In many patients, the eye becomes a visible site of a broader immune pattern.

A terrain-based approach evaluates the person, not only the eye. Netra Eye Institute considers systemic patterns that may influence ocular inflammation while maintaining the central focus on vision, retinal health, and eye-specific function. This broader view can be particularly useful for recurrent cases where the patient is seeking more than episode-by-episode management.

Key Biological Mechanisms in Uveitis

Uveitis develops through an interaction between immune activation and ocular tissue vulnerability. The exact pattern varies by anatomy and cause, but several biological mechanisms appear repeatedly across inflammatory eye disease. Understanding them helps explain why uveitis needs careful, ongoing care from a specialist.

The mechanisms below are not separate boxes. They overlap. For example, cytokines can disrupt the blood-retinal barrier; barrier disruption can increase oxidative stress; oxidative stress can activate endothelial cells; endothelial activation can increase immune-cell trafficking; and recurrent inflammatory events can weaken neural and retinal resilience. The clinical expression may be redness, pain, light sensitivity, floaters, blurred vision, macular swelling, reduced contrast, or visual fatigue, but the underlying biology is multi-dimensional.

Ocular Immune Privilege Breakdown

The eye normally limits inflammatory activity to protect transparent and neural tissues. In uveitis, immune privilege becomes insufficient or disrupted. This allows immune cells and inflammatory mediators to enter ocular compartments and interact with iris, ciliary body, choroid, retina, vitreous, or optic-nerve tissues.

Regulated immune signaling, healthy circulation, intact barriers and adequate metabolic support all help the eye stay calm. When these protective layers are strained, the eye becomes more reactive to triggers that might otherwise be tolerated.

T-Cell and Macrophage Activation

Many forms of noninfectious uveitis involve T-cell activation and recruitment of macrophages or monocytes. These cells can release cytokines, increase tissue reactivity, and perpetuate inflammation. Th1 and Th17 pathways are often discussed in autoimmune uveitis biology.

Medicines that calm the immune system, prescribed by your specialist, target this activity. NRT does not act on these immune cells; it offers supportive care for general health.

Cytokine and Chemokine Signaling

Cytokines and chemokines serve as inflammatory messengers. IL-6, TNF-alpha, IL-17, IL-23, interferon-gamma, MCP-1, and related mediators may influence immune-cell recruitment, vascular permeability, tissue edema, and inflammatory persistence.

Blood-Ocular Barrier Leakage

Inflammation can loosen tight junctions and alter endothelial or epithelial barrier behavior. Leakage across the blood-aqueous or blood-retinal barrier can increase proteins, cells, and fluid in ocular spaces, contributing to haze, flare, retinal thickening, or macular dysfunction.

Barrier leakage is one reason uveitis needs close follow-up. When barriers are fragile, even low-grade inflammation can have outsized visual consequences.

Retinal Endothelial Activation

Retinal vascular endothelial cells are not passive tubes. Under inflammatory stress they may express adhesion molecules, respond to cytokines, alter permeability, and participate in leukocyte trafficking. This mechanism links uveitis to retinal vascular leakage and vasculitic patterns.

Oxidative Stress and Lipid Peroxidation

Reactive oxygen species can rise during inflammation, damaging lipids, proteins, mitochondria, and cellular membranes. Because retinal tissue is rich in oxygen-consuming neurons and polyunsaturated lipids, oxidative stress can be visually significant.

Retinal cells and uveal tissues have a heavy energy demand, which makes them sensitive to oxidative stress. NRT offers nutrition guidance, such as eating foods rich in antioxidants, as part of general health support; it is not a treatment for the inflammation.

Mitochondrial Energy Stress

Photoreceptors, retinal ganglion cells, ciliary tissues, and retinal pigment epithelial cells require high energy. Inflammatory stress can impair mitochondrial function, reduce cellular repair capacity, and worsen fatigue-like visual symptoms such as dimness, poor contrast, or slow recovery after glare.

Choroidal and Retinal Perfusion Disturbance

Inflammation can affect vascular tone, capillary flow, tissue oxygenation, and fluid movement. In posterior or intermediate uveitis, vascular instability may contribute to retinal swelling, optic-disc leakage, or visual fluctuation.

Neuroretinal Injury and Functional Vision Loss

Uveitis can affect visual function by disturbing retinal signaling, macular structure, optic-nerve health, or vitreoretinal clarity. Functional symptoms may persist when inflammation appears quieter, especially if the macula, optic nerve, or retinal microvasculature has been involved.

Systemic Immune Cross-Talk

The eye may reflect immune patterns elsewhere in the body. Gut barrier integrity, systemic cytokine load, chronic inflammatory disease, infection-related immune activation, metabolic stress, and sleep disturbance can influence the threshold for ocular inflammation.

This is why the NRT evaluation pays attention to the patient beyond the eye. Patterns of digestion, sleep, stress, energy, inflammatory history, and constitutional tendencies may help explain why some patients flare repeatedly while others do not.

What Is Netra Restoration Therapy for Uveitis?

Netra Restoration Therapy is Netra Eye Institute's integrative care program, with attention to general health factors such as circulation, sleep, stress, diet and metabolism. For uveitis, it is supportive care alongside your uveitis specialist, not a treatment for the inflammation. The program is personalized, because uveitis can present as anterior, intermediate, posterior, or diffuse inflammation; it can be acute or chronic; and it can occur with different degrees of retinal, macular, vascular, or optic-nerve involvement.

Treating each flare is the job of your uveitis specialist. Alongside that care, NRT asks broader questions about general health: How are sleep, stress and digestion? Are there other health conditions your doctors should know about? Are there habits, such as smoking, that are worth changing?

The specific therapies used in NRT vary with the patient's presentation and clinical judgment. The program may include an integrative eye assessment, acupuncture, Ayurvedic and Traditional Chinese Medicine approaches, nutrition and herbal support when appropriate, and guidance on sleep, daily rhythm and stress. These are offered as supportive care, and your specialist should know about any herbs or supplements you take.

Because uveitis can threaten vision, NRT should be integrated responsibly. A patient with active or sudden symptoms should receive prompt ophthalmic evaluation. NRT is best understood as supportive care alongside the treatment your uveitis specialist prescribes. It has not been shown to reduce flares or improve vision, and it is never a reason to delay, lower or stop steroid or immune treatment.

How NRT Fits Alongside Uveitis Treatment

The phrase biological terrain refers to the internal conditions that shape how the eye responds to stress. In uveitis, the terrain includes immune regulation, vascular behavior, barrier function, tissue oxygenation, mitochondrial capacity, oxidative-stress balance, and systemic inflammatory threshold. A patient may have the same diagnosis as another patient but a very different terrain. One person may have strong autoimmune features; another may have recurrent anterior inflammation triggered by stress and sleep loss; another may have posterior involvement with vascular leakage; another may have persistent visual fatigue after the eye appears quiet. NRT takes these differences into account when planning supportive care.

Supporting the terrain cannot promise that inflammation will not come back, and no study has shown that NRT prevents flares or improves vision in uveitis. Its aim is supportive: attention to the general health factors that many patients link with their flares, such as sleep, stress and diet, alongside the treatment your specialist prescribes. Uveitis can have complex causes, and some cases need medical supervision for a long time.

Immune Balance

Immune balance is central to uveitis because the eye must defend itself without creating inflammatory injury. Steroids and other medicines prescribed by your specialist are what control the inflammation. NRT pays attention to stress, sleep, digestion and constitutional factors as supportive care; it has not been shown to change the immune response in the eye.

In recurrent uveitis, the periods between flares matter too. Keeping to your specialist's follow-up plan, and reporting new symptoms early, helps catch the next flare quickly. NRT can offer supportive care with sleep, stress and general health during these periods.

Circulation

The uvea, retina, and optic nerve depend on healthy circulation. Inflammatory tissue requires oxygen, nutrient delivery, and efficient removal of metabolic byproducts. At the same time, inflamed vessels can become leaky and unstable. NRT pays attention to general factors linked with circulation, such as blood pressure, activity and not smoking; it has not been shown to improve blood flow in the eye.

Blood vessel changes matter most when uveitis involves the back of the eye, the macula, retinal vessels, or optic nerve. In such cases, vision may be affected not only by inflammatory cells but also by vascular leakage, reduced tissue oxygenation, or impaired metabolic exchange.

Leaky Barriers in the Eye

The blood-aqueous and blood-retinal barriers help keep the inside of the eye clear. When uveitis makes them leaky, proteins, cells and fluid can build up where they should not, causing haze or swelling at the center of the retina. Controlling the inflammation with the treatment your specialist prescribes is what lets the barriers settle.

Repeated flares, swelling at the center of the retina and lingering haze need close follow-up with your uveitis specialist, because they may need more treatment, such as anti-inflammatory medicines, steroid injections or implants. Integrative care has not been shown to repair a leaky barrier, and NRT is offered only alongside that treatment.

When Vision Feels Strained After a Flare

Inflammation increases the metabolic demand of ocular tissues. Retinal neurons, photoreceptors, retinal pigment epithelial cells, and vascular endothelial cells must continue functioning even in a chemically stressful environment. NRT offers nutrition and lifestyle guidance as part of general health support; it has not been shown to speed the eye's recovery from inflammation.

Patients often describe vision after a flare as not simply blurred, but strained, dim, slow or unstable. These symptoms deserve a check by your specialist, because some causes are treatable. NRT can be offered as supportive care alongside your specialist's care.

When Vision Problems Linger After a Flare

When uveitis affects the retina, macula, optic disc or retinal blood vessels, some vision problems can last after the flare settles. These include reduced contrast, visual fatigue, lingering blur and slow recovery after bright light. Swelling at the center of the retina, called uveitic macular edema, is the most common cause of vision loss in uveitis, and it can linger or come back after the inflammation has settled. It can be treated, so have any new or lingering blur checked promptly by your eye doctor, usually with an OCT scan, which takes detailed pictures of the retina. NRT does not repair the retina; it is offered as supportive care for comfort and general health while your specialist treats the eye.

The retina is living nerve tissue, so changes in vision after a flare deserve the same attention as redness or pain.

Whole-Body Health

Uveitis may reflect systemic inflammatory patterns even when the first symptom appears in the eye. NRT considers sleep, digestion, stress physiology, constitutional patterns, nutrition, metabolic health, and systemic inflammatory history. This does not replace medical diagnosis or treatment, and it has not been shown to make flares less likely.

The eye may be the most urgent site of inflammation, but the immune system that drives it belongs to the whole person. That is why your specialist may check for conditions elsewhere in the body, such as joint, bowel or skin disease, that can be linked with uveitis.

Patient-Centered Goals of NRT for Uveitis

• Support general health, such as sleep, stress and diet, alongside the patient's medical treatment.
• Pay attention to general health factors linked with circulation, such as blood pressure, activity and not smoking.
• Offer practical comfort advice, such as managing light sensitivity and screen strain.
• Offer nutrition and lifestyle guidance as part of general health support.
• Encourage patients to report lingering vision changes promptly so their specialist can look for treatable causes.
• Help patients notice possible flare triggers, such as stress or poor sleep, and discuss them with their specialist.
• Encourage regular follow-up with the uveitis specialist, even when the eye feels quiet.

Frequently Asked Questions on Uveitis

Selected References for Scientific Support

• Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. American Journal of Ophthalmology. 2005;140(3):509-516.
• Taylor AW, Kaplan HJ. Ocular immune privilege in the year 2010: ocular immune privilege and uveitis. Ocular Immunology and Inflammation. 2010;18(6):488-492. doi:10.3109/09273948.2010.525730.
• Caspi RR. A look at autoimmunity and inflammation in the eye. Journal of Clinical Investigation. 2010;120(9):3073-3083. doi:10.1172/JCI42440.
• Weinstein JE, Pepple KL. Cytokines in uveitis. Current Opinion in Ophthalmology. 2018;29(3):267-274. doi:10.1097/ICU.0000000000000466.
• Kim J, Chun J, Ahn M, Jung K, Moon C, Shin T-K. Blood-retina barrier dysfunction in experimental autoimmune uveitis: the pathogenesis and therapeutic targets. Anatomy & Cell Biology. 2022;55(1):20-27. doi:10.5115/acb.21.227.
• Ferreira LB, Williams KA, Best G, Haydinger CD, Smith JR. Inflammatory cytokines as mediators of retinal endothelial barrier dysfunction in non-infectious uveitis. Clinical & Translational Immunology. 2023;12(12):e1479. doi:10.1002/cti2.1479.
• Tomkins-Netzer O, Niederer R, Greenwood J, Fabian ID, Serlin Y, Friedman A, Lightman S. Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy. Progress in Retinal and Eye Research. 2024;99:101245. doi:10.1016/j.preteyeres.2024.101245.
• Chistyakov DV, Chistyakov VV, Astakhova AA, et al. Targeting oxidative stress and inflammation in the eye. International Journal of Molecular Sciences. 2024;25: review article on ocular oxidative stress and inflammation.
• Xiao J, Zhao C, Cheng G, Song H, Zhang Y, Zhang M, et al. Multiple cytokine analysis of aqueous humor in uveitis with or without secondary glaucoma. BMC Ophthalmology. 2024;24:451. doi:10.1186/s12886-024-03691-4.
• Asghar MA, et al. Infectious uveitis: a comprehensive systematic review of clinical patterns and etiologies. 2024; PMC-indexed systematic review.
• Thorne JE, Suhler EB, Skup M, Tari SR, Macaulay D, Chao J, Ganguli AX. Prevalence of noninfectious uveitis in the United States: a claims-based analysis. JAMA Ophthalmology. 2016;134(11):1237-1245. doi:10.1001/jamaophthalmol.2016.3229.
• Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis. Frontiers in Medicine. 2021;8:695904. doi:10.3389/fmed.2021.695904.
• Basu S, et al. Intraocular immune response in human uveitis. American Journal of Ophthalmology. 2024; perspective/review article based on ARVO 2023 Special Interest Group discussions.
• Nussenblatt RB, Whitcup SM. Uveitis: Fundamentals and Clinical Practice. Elsevier/Saunders. Authoritative clinical text on uveitis classification, mechanisms, and clinical features.
• Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor-alpha in experimental autoimmune uveoretinitis. Progress in Retinal and Eye Research. 2004;23(6):617-637. doi:10.1016/j.preteyeres.2004.06.003.
• National Eye Institute. Uveitis. Updated December 4, 2024.
• Mayo Clinic. Uveitis: Diagnosis and treatment. September 20, 2025.
• Prevent Blindness. How Do Eye Doctors Treat Uveitis? Updated July 20, 2026.
• Cleveland Clinic. Uveitis. Updated March 25, 2024.
• NHS. Uveitis. Reviewed March 20, 2024.
• Harrogate and District NHS Foundation Trust. Acute Anterior Uveitis: Patient and Carer Information. Undated leaflet, accessed October 27, 2026.
• Zierhut M, Deuter C, Murray PI. Classification of uveitis: current guidelines. European Ophthalmic Review. 2007:77-78.
• Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA. 2019;322(10):936-945.
• Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. New England Journal of Medicine. 2016;375(10):932-943.
• US Food and Drug Administration. Orphan Drug Designations and Approvals: adalimumab (Humira). Approved June 30, 2016.
• Lin P, Loh AR, Margolis TP, Acharya NR. Cigarette smoking as a risk factor for uveitis. Ophthalmology. 2010;117(3):585-590.
• Rademacher J, Poddubnyy D, Pleyer U. Uveitis in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease. 2020;12:1759720X20951733.
• Wu S, Liqun C, Wanyu Z, et al. Efficacy and safety of Jiawei Simiaoyongan granules in the treatment of non-infectious anterior uveitis: a randomized open-label trial. Journal of Traditional Chinese Medicine. 2026;46(2):418-426.
• NHS. Conjunctivitis. Reviewed April 23, 2024.
• NHS. Red eye. Reviewed October 27, 2025.
• National Institutes of Health Office of Dietary Supplements. Dietary Supplements: What You Need to Know. Updated January 4, 2023.
• Aneurin Bevan University Health Board. Anterior Uveitis/Iritis. Patient information leaflet ABUHB/PIU:652/5, issued April 5, 2026.
• Hull University Teaching Hospitals NHS Trust. Uveitis. Patient leaflet HEY118/2025, published September 16, 2021, updated March 31, 2025.
• Cleveland Clinic. Iritis. Updated November 11, 2025.
• Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care & Research. 2019;71(6):703-716.
• Durrani OM, Tehrani NN, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. British Journal of Ophthalmology. 2004;88(9):1159-1162.
• Massa H, Pipis SY, Adewoyin T, et al. Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clinical Ophthalmology. 2019;13:1761-1777.